ORCID Profile
0000-0002-8083-2864
Current Organisation
Uppsala University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 06-2020
Publisher: F1000 Research Ltd
Date: 03-10-2023
Publisher: F1000 Research Ltd
Date: 08-11-2021
DOI: 10.12688/F1000RESEARCH.74502.1
Abstract: Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For ex le, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.
Publisher: IOP Publishing
Date: 04-02-2020
Abstract: Dynamic resistance can be observed in a superconducting tape carrying a DC current which is exposed to an oscillating magnetic field. This effect is attributed to the interaction between the transport current and moving fluxons, and can occur in various superconducting components including high temperature superconducting (HTS) flux pumps, fast-r ing magnets and HTS rotating machines. Although conventionally expressed in terms of a DC ‘resistance,’ the phenomenon is inherently transient in nature, and the voltage drop across the superconductor follows a time-dependent periodic waveform. Here we present experimental measurements of the dynamic resistance of different REBCO tapes carrying a DC current and exposed to an oscillating perpendicular field. Measurements of both the transient voltage waveforms and the time-averaged DC resistances are compared with numerical finite element simulations obtained using the H -formulation. We observe clear variations between the voltage response from different tapes, which can be understood in terms of their differing J c ( B , θ ) dependence. In particular, a key feature of the experimentally measured waveforms is the emergence of a split ‘double peak’ at higher applied fields. Graphical visualisations of the finite element data show that this coincides with a periodic increase in J c ( B, θ ) throughout the tape. This occurs during each cycle at those times when the applied field falls below the shielding threshold of the tape (as the penetrating field within the tape then approaches zero). Our findings show that models which assume a constant J c irrespective of local field strength cannot capture the full range of behaviour observed by experiment. This emphasises the importance of employing experimentally measured J c ( B, θ ) data when simulating transient effects in HTS materials.
Publisher: IOP Publishing
Date: 23-06-2021
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 08-2021
Publisher: Oxford University Press (OUP)
Date: 21-04-2017
DOI: 10.1093/JAMIA/OCX038
Abstract: Objective:We provide an e-Science perspective on the workflow from risk factor discovery and classification of disease to evaluation of personalized intervention programs. As case studies, we use personalized prostate and breast cancer screenings. Materials and Methods:We describe an e-Science initiative in Sweden, e-Science for Cancer Prevention and Control (eCPC), which supports biomarker discovery and offers decision support for personalized intervention strategies. The generic eCPC contribution is a workflow with 4 nodes applied iteratively, and the concept of e-Science signifies systematic use of tools from the mathematical, statistical, data, and computer sciences. Results:The eCPC workflow is illustrated through 2 case studies. For prostate cancer, an in-house personalized screening tool, the Stockholm-3 model (S3M), is presented as an alternative to prostate-specific antigen testing alone. S3M is evaluated in a trial setting and plans for rollout in the population are discussed. For breast cancer, new biomarkers based on breast density and molecular profiles are developed and the US multicenter Women Informed to Screen Depending on Measures (WISDOM) trial is referred to for evaluation. While current eCPC data management uses a traditional data warehouse model, we discuss eCPC-developed features of a coherent data integration platform. Discussion and Conclusion:E-Science tools are a key part of an evidence-based process for personalized medicine. This paper provides a structured workflow from data and models to evaluation of new personalized intervention strategies. The importance of multidisciplinary collaboration is emphasized. Importantly, the generic concepts of the suggested eCPC workflow are transferrable to other disease domains, although each disease will require tailored solutions.
No related grants have been discovered for Ola Spjuth.